Application of Nano-Antibodies for Cancer Immunotherapy

Abstract

Abstract Summary By inhibiting intracellular KRAS and STAT3, SBT-100 suppresses the growth of human tumors in vivo, decreases VEGF and PD-L1 expression, inhibits IL-6 function in cancers, suppresses IL-17, GM-CSF, IFN-gamma, IL-1-alpha, and downregulates Th17 cells. Purpose of Review Two VHH (camelid heavy chain variable region) antibodies are being used to treat patients with the thrombotic disorder and rheumatoid arthritis; however, no VHHs are currently being used to treat cancer patients. The purpose of this review is to discuss VHHs that have been developed to target intracellular oncoproteins such as KRAS and STAT3 for cancer therapy. Recent Findings Various groups are working on optimizing cell-penetrating antibodies to target intracellular KRAS and STAT3 but are using non-VHH platforms. SBT-100 is a monomeric, bi-specific VHH that penetrates the cell membrane and BBB to give a therapeutic response against human cancers.